Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Saibeni

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Journal of Gastroenterology and Hepatology|June 23, 2021
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapySandro Ardizzone, Francesca Ferretti, Maria Camilla Monico, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 6, 2017
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)Livia Biancone, Vito Annese, Sandro Ardizzone, et al.
Diagnostics (Basel, Switzerland)|February 13, 2026
Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort StudyDavide Scalvini, Stiliano Maimaris, Elisa Stasi, et al.
Gut|May 2, 2020
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD studyCristina Bezzio, Simone Saibeni, Angela Variola, et al.
Journal of Clinical Medicine|January 8, 2025
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre StudyBernadett Farkas, Talat Bessissow, Jimmy K Limdi, et al.
United European Gastroenterology Journal|November 18, 2020
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD studyDaniela Pugliese, Giuseppe Privitera, Francesca Rogai, et al.
European Journal of Clinical Investigation|July 9, 2024
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME studyFerdinando D'Amico, Luca Massimino, Giulia Palmieri, et al.
Inflammatory Bowel Diseases|August 24, 2018
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across ItalyAlessandro Armuzzi, Gionata Fiorino, Angela Variola, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 31, 2024
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Incà, et al.
European Journal of Gastroenterology & Hepatology|September 27, 2022
Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison studyAndrea Cassinotti, Nicolò Mezzina, Annalisa De Silvestri, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Journal of Gastroenterology and Hepatology|June 23, 2021
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapySandro Ardizzone, Francesca Ferretti, Maria Camilla Monico, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 6, 2017
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)Livia Biancone, Vito Annese, Sandro Ardizzone, et al.
Diagnostics (Basel, Switzerland)|February 13, 2026
Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort StudyDavide Scalvini, Stiliano Maimaris, Elisa Stasi, et al.
Gut|May 2, 2020
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD studyCristina Bezzio, Simone Saibeni, Angela Variola, et al.
Journal of Clinical Medicine|January 8, 2025
Real-World Effectiveness and Safety of Selective JAK Inhibitors in Ulcerative Colitis and Crohn's Disease: A Retrospective, Multicentre StudyBernadett Farkas, Talat Bessissow, Jimmy K Limdi, et al.
United European Gastroenterology Journal|November 18, 2020
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD studyDaniela Pugliese, Giuseppe Privitera, Francesca Rogai, et al.
European Journal of Clinical Investigation|July 9, 2024
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME studyFerdinando D'Amico, Luca Massimino, Giulia Palmieri, et al.
Inflammatory Bowel Diseases|August 24, 2018
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across ItalyAlessandro Armuzzi, Gionata Fiorino, Angela Variola, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 31, 2024
Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)Gaetano Bergamaschi, Fabiana Castiglione, Renata D'Incà, et al.
European Journal of Gastroenterology & Hepatology|September 27, 2022
Continuous clinical remission with biologics in ulcerative colitis: the 'AURORA' comparison studyAndrea Cassinotti, Nicolò Mezzina, Annalisa De Silvestri, et al.
Pageof 11